2020-China’s Biomedicine Industry Ushers New Upsurge of IPO listings
Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange was officially opened for trading and it has since a brought new vitality to China's capital market and the development of China's technology. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.